WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc.  (NYSE American:CVRS), a leading developer of precision vascular robotics, today announced the execution of a private placement transaction with a large institutional investor pursuant to which it will sell and issue an aggregate of 10,872,716 shares of its common stock, at a purchase price of $1.3796 per share, resulting in aggregate gross proceeds to the Company of approximately $15 million, which the Company expects to receive during the day. The net proceeds are expected to be approximately $14.8 million. The Company intends to use the proceeds for general corporate purposes.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second-generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit www.corindus.com, and follow @CorindusInc.